| |
| Carl Zeiss Meditec - Brief Profile |
| |
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies.
The company supplies innovative technologies and application- oriented solutions which enable doctors to improve the quality of life of their patients. The company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of microsurgery the company provides innovative visualization solutions. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.
The company's around 2,200 employees generated revenue of about EUR 676,7 million in fiscal year 2009/10 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.
Thirty-five percent of Carl Zeiss Meditec’s shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups engaged in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. During fiscal year 2008/09 the group of companies generated revenues of around EUR 2.1 billion. From fiscal year 2010/11 onward, eyeglass lens manufacturer Carl Zeiss Vision will be integrated as an autonomous business group (revenues of EUR 880 million in fiscal year 2008/09). The Carl Zeiss Group now has approximately 24,000 employees, including more than 10,000 in Germany. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).
Top | |
|